Axon Enterprise, Inc. (NASDAQ:AXON) Receives Average Rating of “Buy” from Brokerages

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have earned a consensus rating of “Buy” from the fourteen research firms that are covering the company, MarketBeat.com reports. Fourteen equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $504.92.

Several equities analysts recently commented on the company. TD Cowen began coverage on Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. Robert W. Baird upped their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. JMP Securities lifted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Northland Securities raised their price objective on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th.

Axon Enterprise Stock Down 0.5 %

AXON opened at $610.32 on Friday. The firm has a market capitalization of $46.54 billion, a P/E ratio of 157.71, a price-to-earnings-growth ratio of 6.09 and a beta of 1.04. Axon Enterprise has a one year low of $247.04 and a one year high of $698.67. The company has a fifty day moving average price of $617.65 and a 200-day moving average price of $469.56. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Insiders Place Their Bets

In related news, insider Jeffrey C. Kunins sold 21,834 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the sale, the insider now owns 154,394 shares of the company’s stock, valued at $91,691,508.72. The trade was a 12.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now directly owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,545 shares of company stock worth $30,721,337 over the last three months. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently bought and sold shares of the company. Asset Dedication LLC lifted its holdings in shares of Axon Enterprise by 11.3% during the fourth quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 18 shares in the last quarter. Insigneo Advisory Services LLC lifted its stake in Axon Enterprise by 1.4% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock valued at $627,000 after acquiring an additional 22 shares during the period. Menard Financial Group LLC boosted its holdings in shares of Axon Enterprise by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock valued at $1,204,000 after acquiring an additional 24 shares during the last quarter. PFG Investments LLC grew its stake in shares of Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after acquiring an additional 25 shares during the period. Finally, Gladstone Institutional Advisory LLC raised its holdings in shares of Axon Enterprise by 1.6% during the third quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 26 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.